SENZAGEN AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.38 SEK | +2.90% |
|
-7.54% | -12.36% |
| Mar. 25 | Senzagen Receives Follow-Up Order Worth SEK 0.8 Million from the Global Chemicals Leader | CI |
| Mar. 22 | SenzaGen AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2024 * | 67.55M 6.26M | Sales 2025 * | 91.65M 8.49M | Capitalization | 154M 14.3M |
|---|---|---|---|---|---|
| Net income 2024 * | -15M -1.39M | Net income 2025 * | -4M -371K | EV / Sales 2024 * | 2.17 x |
| Net cash position 2024 * | 8M 741K | Net cash position 2025 * | 9M 834K | EV / Sales 2025 * | 1.59 x |
| P/E ratio 2024 * |
-10.3
x | P/E ratio 2025 * |
-37.5
x | Employees | 34 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 61.56% |
More Fundamentals
* Assessed data
More news
Latest transcript on SenzaGen AB
More press releases
| 1 day | +2.90% | ||
| 1 week | -7.54% | ||
| Current month | -4.49% | ||
| 1 month | +2.90% | ||
| 3 months | +0.95% | ||
| 6 months | -10.64% | ||
| Current year | -12.36% |
1 week
6.00
6.64
1 month
6.008.00
Current year
5.468.00
1 year
5.4613.10
3 years
5.4626.10
5 years
5.4634.25
10 years
5.4674.00
| Managers | Title | Age | Since |
|---|---|---|---|
Peter Nählstedt
CEO | Chief Executive Officer | 50 | 17-12-31 |
Marianne Olsson
DFI | Director of Finance/CFO | 63 | 16-10-31 |
Henrik Johansson
CTO | Chief Tech/Sci/R&D Officer | 42 | 13-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | 76 | 10-08-17 | |
| Director/Board Member | 59 | 14-10-14 | |
Paula Zeilon
BRD | Director/Board Member | 62 | 19-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 6.38 | +2.90% | 82,499 |
| 24-04-22 | 6.2 | 0.00% | 13,251 |
| 24-04-19 | 6.2 | -4.62% | 23,249 |
| 24-04-18 | 6.5 | -0.91% | 12,792 |
| 24-04-17 | 6.56 | -4.93% | 13,850 |
Delayed Quote Nasdaq Stockholm, April 23, 2024 at 11:29 am EDT
More quotes
SenzaGen AB is a Sweden-based company, which specializes in immunology, technology and genomics. The Company markets, sells and performs the in vitro Genomic Allergen Rapid Detection (GARD) sensitization test through its own laboratory and through licensed Contract Research Organization (CROs). SenzaGen AB makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals people come in contact with in their daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The Company sells the tests in Sweden and the United States, and also sells through partners in several other countries. SenzaGen AB has a subsidiary in San Francisco, the United States.
Calendar
2024-05-15
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -12.36% | 13.74M | |
| -14.13% | 11.33B | |
| +45.76% | 3.16B | |
| -35.86% | 2.14B | |
| -18.27% | 2.04B | |
| -27.92% | 1.49B | |
| +18.02% | 975M | |
| -3.49% | 731M | |
| -31.42% | 423M | |
| +26.64% | 371M |
- Stock Market
- Equities
- SENZA Stock
